Article About Groundbreaking Results from Study of Jaguar Health’s Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publicati…

Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines ...

KFSHRC Advances Intestinal Transplantation Care Through a Specialized National Program

King Faisal Specialist Hospital & Research Centre continues to advance complex transplant medicine through its Intestinal Transplant Program, a highly specialized service designed to manage patients ...
Kaleido Scope

Intestinal Rehab Program

Intestinal failure is defined as having an intestinal condition which renders a child unable to maintain adequate hydration and meet calorie absorption needs sufficient for growth. This results in ...
Business Insider

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially ...

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first short bowel syndrome with intestinal failure (SBS-IF) ...
The Herald-Mail

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal ...

SBS-IF is the second orphan disease target indication for Jaguar’s intestinal failure program, which includes microvillus inclusion disease (MVID) – for which the company completed a meeting in ...
European Medical Journal

Alzheimer’s Disease Gut Microbiome Signals in Colon

Transverse colon samples from confirmed Alzheimer’s disease cases showed distinct gut microbiome and proteomic shifts, ...